Rapidpulse Inc

Rapidpulse, Inc. is a privately held, venture-backed medical device company headquartered in Miami, Florida. A spinout from the medical device incubator Syntheon 2.0, LLC, Rapidpulse was established to develop new stroke therapies and announced its initial $15 million Series A financing in June 2021. Its investors include Santé Ventures, Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures. As a pre-commercial entity, its revenue and employee count are not publicly available.

The company's operations are focused on developing and commercializing the RapidPulse™ Aspiration System, a medical device for treating acute ischemic stroke. The system is designed to perform mechanical thrombectomy—the removal of blood clots from vessels in the brain. Its patented technology uses a novel method of "cyclic" or "pulsed" aspiration, which delivers high-frequency vacuum forces intended to remove clots more rapidly and completely than traditional static aspiration devices. The complete system includes a proprietary pump, specialized catheters, and tubing sets. The RapidPulse system is investigational and not yet cleared for commercial sale in any jurisdiction; the company received FDA approval in late 2024 to begin a pivotal clinical study.

Rapidpulse's patent litigation posture is that of an operating company defending its intellectual property. The company has appeared in the US patent litigation database once as a defendant and never as a plaintiff. This is consistent with a technology startup defending its patent portfolio against challenges from established competitors rather than acting as a patent-assertion entity.

The company's single tracked case is an appeal in Penumbra Inc v. Rapidpulse Inc. This case stems from an inter partes review (IPR) initiated at the Patent Trial and Appeal Board (PTAB) by Penumbra, a much larger competitor in the neurovascular device market. Penumbra successfully challenged and invalidated a Rapidpulse patent related to its thrombectomy system. Rapidpulse appealed the decision to the Court of Appeals for the Federal Circuit. The competitive landscape shifted significantly in early 2026, when Boston Scientific announced its acquisition of Penumbra for approximately $14.5 billion, a deal approved by Penumbra shareholders in May 2026.